To The Moon

Sign Up
CommunityConnect with experts, uncover more opportunities
DJIA
--
--
DJIA
NASDAQ
--
--
NASDAQ
S&P 500
--
--
S&P 500
HSI
--
--
HSI
Straits Times Index
--
--
Straits Times Index
S&P/ASX 200
--
--
S&P/ASX 200
168
General
苏36
·
10-19
India’s biggest opportunity may also be its biggest investment trap. The UTI India Nifty 50 Index ETF VCC launches on SGX on 12 November, giving Singapore investors access to 50 leading Indian companies without an Indian brokerage account. India’s domestic consumption, infrastructure spending and financial-sector expansion offer compelling long-term growth drivers. Its different sector composition may also diversify portfolios heavily concentrated in US technology stocks. But here’s the catch: economic growth does not automatically translate into stock market returns. Currency depreciation can erode gains, valuations still matter, and past outperformance guarantees nothing. My view? India deserves consideration as a long-term portfolio diversifier, but investors should avoid confusing a p

India's 50 Blue-Chips on SGX: UTI India Nifty 50 Index ETF VCC

@Tiger_SG：
Access India's largest listed companies in USD or SGD, during Singapore trading hours Receive up to USD$600^ Cash Coupon when you subscribe to the UTI India Nifty 50 Index ETF VCC during the Initial Offer Period. Introducing the UTI India Nifty 50 Index ETF VCC On 12 November 2026, India's 50 biggest companies come to SGX. The UTI India Nifty 50 Index ETF VCC is the first Nifty 50 ETF listed in Singapore. With this ETF, you can invest in India's largest companies using your existing Singapore brokerage account, during Singapore trading hours, in US (ticker: NIU) or S$ (ticker: NIF). The Fund's investment objective is to track as closely as possible, before fees and expenses, the returns of the Nifty 50 Index (the "Index"). The Index represents 50 of the largest and most liquid companies li
India's 50 Blue-Chips on SGX: UTI India Nifty 50 Index ETF VCC
India’s biggest opportunity may also be its biggest investment trap. The UTI India Nifty 50 Index ETF VCC launches on SGX on 12 November, giving Si...
TOPOswaldFinger: Currency is the whole game here. If the rupee keeps leaking, that diversification can feel a lot thinner than the headline Nifty return
2
Report
527
General
Shyon
·
10-19
I am most interested in $Salesforce.com(CRM)$ because I believe AI could strengthen established enterprise software companies rather than simply replace them. Salesforce already has a strong customer base, valuable business data and deeply integrated workflows, giving it potential advantages in the AI era. However, I will not buy simply because $Bank of America(BAC)$ upgraded the stock to Buy with a $285 price target. I want to see clear evidence that its AI products can generate meaningful incremental revenue and earnings growth, rather than just increasing costs and expectations. For me, the key is whether Salesforce can turn its AI capabilities into sustainable monetization. I remain selective with
I am most interested in $Salesforce.com(CRM)$ because I believe AI could strengthen established enterprise software companies rather than simply re...
# Winning Trades
TOPhappiness000: CRM AI upside lives in pricing power inside existing workflows, not shiny features. If that monetization shows up cleanly, the moat gets a lot harder to crack
4
Report
400
General
HODL2MOON
·
10-19 21:15
Buying the Dip? The Biggest Mistake Is Buying Without a Plan The market is fearful. But before buying the dip, ask yourself one question: would you still want to own this stock if it fell another 15%? After last week’s sharp technology sell-off, investors have a familiar dilemma: buy now, wait for a deeper correction, or sit on the sidelines because there is little cash left. The fear is real. On October 16, the VIX jumped more than 21% to close near 20, while CNN’s Fear & Greed Index dropped to 18, its Extreme Fear zone. The VIX eased to around 18.7 on October 19, but sentiment remained weak. Is this a buying opportunity? Potentially. But extreme fear is a signal to reassess prices, not proof that the market has bottomed. 1. A market correction is normal, not necessarily a crisis Inve
Buying the Dip? The Biggest Mistake Is Buying Without a Plan The market is fearful. But before buying the dip, ask yourself one question: would you...
# 🎁 Write & Win | Buying the Dip? What Are You Buying?
TOPJoBloor: Valuation matters most to me. For AI chips, the real question is whether PEG has reset enough — fear helps, but it still does not make Nvidia cheap.
1
Report
154
General
苏36
·
10-19 23:18
Tesla’s $158 billion compensation headline is less about money earned today and more about the future investors are being asked to believe in. Musk’s performance-based package is essentially a decade-long bet on Tesla transforming from an EV manufacturer into an AI, robotics, and autonomous mobility powerhouse. The potential rewards are enormous, but so are the execution risks. Reaching an $8.5 trillion valuation requires much more than ambitious presentations: Robotaxis must scale commercially, Optimus must become a viable business, and massive investments must translate into sustainable profits. Here’s the real investor dilemma: Tesla shareholders are not just betting on a company; they are betting on Musk’s ability to turn technological promises into measurable cash flows. The $158 bil

Musk's $158B Pay Package: A $1 Trillion Bet on Tesla's Future

@AI_FocusedTrader：
$Tesla Motors(TSLA)$ announcement: Elon Musk’s 2025 compensation includes $158.36 billion in stock awards. Tesla (TSLA.US) will hold its annual shareholder meeting on December 3. Musk's $158B Pay Package: A $1 Trillion Bet on Tesla's Future What the $158.36 billion represents This is the total compensation Tesla booked for Musk in 2025 following shareholder approval of his new 10-year pay plan in November 2025, precisely $158,359,009,867: ~$132 billion: the grant-date fair value of the new 10-year CEO Performance Award, assuming all performance conditions are met; ~$26 billion: an interim supplemental award approved in August 2025 — but Musk forfeited this in April 2026 after his 2018 pay package was reinstated by the courts. Tesla
Musk's $158B Pay Package: A $1 Trillion Bet on Tesla's Future
Tesla’s $158 billion compensation headline is less about money earned today and more about the future investors are being asked to believe in. Musk...
TOPMess0M: Execution risk is the point though - Tesla was never meant to be valued like an EV maker. That package ties Musk to long-term milestones, which is exactly what bulls are paying for
1
Report
5.76K
General
Blinkfans
·
10-20 10:13
$IAU 20261030 77.5 PUT$ 💗🐾 Blink Fans Market Journal: Why I Sold the IAU $77.50 Put 🥇 1. Why am I making this trade now? I decided to sell the IAU $77.50 put expiring on 30 October 2026 because I want to take advantage of the current gold price consolidation while collecting option premium. Instead of rushing to buy gold exposure immediately, I prefer to let the market come closer to my desired entry price and get paid for taking that risk. I sold the put at approximately US$0.89 per share, which represents US$89 in premium before fees for one standard contract covering 100 shares. My trading screenshot showed an unrealized gain of around 1.13% at that point. My plan is to buy back the put later if its price
IAU PUT
10-19 23:48
US20261030 77.5
SidePriceRealized P&L
Sell
Open
0.89--
Closed
Gold Trust Ishares
$IAU 20261030 77.5 PUT$ 💗🐾 Blink Fans Market Journal: Why I Sold the IAU $77.50 Put 🥇 1. Why am I making this trade now? I decided to sell the IAU ...
# Trade Feed: Who is your favorite trader?
TOPWayneEvans: 74.44 is the real line to me. If that support breaks, assignment is fine, but the next step matters more than theta decay here
10
Report
454
General
苏36
·
10-20 11:21
[你懂的]   Intuitive Surgical (ISRG) — Can Surgical Robotics Keep Delivering Growth? While much of Wall Street remains focused on AI chips, data centers, and semiconductor volatility, I want to highlight a different opportunity: Intuitive Surgical (ISRG), a pioneer in robotic-assisted surgery. What makes this company interesting isn't simply its technology. It's the business model behind it. Intuitive Surgical sells sophisticated surgical systems, but it also generates recurring revenue from instruments, accessories, and services. As its installed base grows and more procedures are performed, the company has opportunities to generate revenue long after the initial equipment sale. However, a great business isn't automatically a great investment at every price. With the company a
[你懂的] Intuitive Surgical (ISRG) — Can Surgical Robotics Keep Delivering Growth? While much of Wall Street remains focused on AI chips, data centers...
# 💰Stocks to watch today?(22 October）
TOPCaesarHicks: Forward PE is still rich versus medtech peers, and ISRG usually trades above its own historical median too. Procedure growth can carry a lot, but multiple compression can still mute returns
2
Report
33.08K
General
SG Visual Research
·
10-20 11:29

LMS Compliance Research Update: Growth and Earnings Conversion

$LMS Compliance(LMS.SI)$   LMS Compliance (SGX: LMS) reported 40.5% revenue growth in 1H FY2026. Profit attributable to shareholders rose 12.2%, while core testing revenue declined 2.5%. This video looks at the story behind the numbers: can business growth translate into stronger shareholder earnings? For informational purposes only. Not investment advice.
LMS Compliance Research Update: Growth and Earnings Conversion
TOPEmilyMark: 40.5% top line growth looks flattered to me. Core testing down 2.5% is the bigger tell, so earnings conversion still looks weak
2
Report
340
General
HODL2MOON
·
10-20 12:43
I Bought HOOD Around $95 During the Pullback. Here’s Why I Made the Move I finally started putting some money to work during this pullback. While some investors are waiting for another leg down, I decided to take a position in Robinhood $Robinhood(HOOD)$  around $95. Was it the exact bottom? Probably not something anyone can know in real time. But I did not buy simply because the share price had fallen. I bought because I believe the business still has room to grow, and the pullback gave me an entry point I was more comfortable with. For me, the goal is not to catch the lowest price on the chart. It is to find a business whose future potential justifies the price I am paying. Why HOOD caught my attention Robinhood is no longer just a pla
I Bought HOOD Around $95 During the Pullback. Here’s Why I Made the Move I finally started putting some money to work during this pullback. While s...
# 🎁 Write & Win | Did you buy at the bottom during this recent pullback?
TOPWernerBilly: I care more about how HOOD moves assets into options and crypto than raw user growth. That mix shift is where the margin story gets real
1
Report
281
General
苏36
·
10-20 14:38
Among these eight biotech stocks, I find $PTC Therapeutics (PTCT) most compelling because it already generates commercial revenue rather than relying entirely on future clinical success. Sephience’s growth could support its valuation, although patient retention and revenue guidance remain critical. $Belite Bio (BLTE) offers greater upside ahead of its February 2027 FDA decision, but promising Phase III results cannot eliminate regulatory and valuation risks. Meanwhile, $Trevi Therapeutics (TRVI) and $COMPASS Pathways (CMPS) offer opportunities, but commercialization remains uncertain. My view: PTCT offers clearer execution, while BLTE offers a catalyst-driven investment case. Analyst price targets are scenarios, not guarantees. In biotech, the best opportunity is not necessarily the drug
Among these eight biotech stocks, I find $PTC Therapeutics (PTCT) most compelling because it already generates commercial revenue rather than relyi...
TOPqixoo: BLTE's Phase III visual function signal probably matters more than the market is pricing in. PTCT still feels cleaner on execution, but cash runway is the part I'd keep stress testing
1
Report
271
General
Shyon
·
10-20 15:03
I find $PTC Therapeutics(PTCT)$ and $Belite Bio, Inc.(BLTE)$ particularly interesting. PTCT already has a commercial product generating meaningful revenue, while BLTE offers a major FDA catalyst in February 2027. I generally prefer companies with clear milestones and evidence of commercial demand. However, biotech remains high risk. Even promising clinical results do not guarantee approval or share-price gains. For
I find $PTC Therapeutics(PTCT)$ and $Belite Bio, Inc.(BLTE)$ particularly interesting. PTCT already has a commercial product generating meaningful ...
TOPHunterGame: BLTE's 2027 FDA date is the hook, but discounting that back today still needs a real peak sales case. PTCT having actual revenue just makes the risk/reward cleaner
2
Report
467
Selection
nerdbull1669
·
10-20 10:30

Navigating Monetary Uncertainty: Analysis of the October 2026 FOMC Decision

Federal Reserve Chair Kevin Warsh declined to provide forward guidance or signal whether the central bank will raise or hold interest rates at the upcoming October 27–28, 2026 FOMC meeting, stating at the IMF and World Bank annual meetings in Bangkok that he does not "prejudge" policy decisions. In this article, we would like to share our understanding the policy mechanics, positioning strategies, and sectoral implications surrounding this pivotal meeting. I. Macroeconomic Context & The October FOMC Framework The Federal Open Market Committee enters its October 27–28, 2026 meeting against one of the most ambiguous macroeconomic backdrops in recent monetary history. Federal Reserve Chair Kevin Warsh’s explicit refusal to offer forward guidance during his remarks at the IMF and World Ban
Navigating Monetary Uncertainty: Analysis of the October 2026 FOMC Decision
# Earnings Split the Tape: Is Cash the Real Winner?
TOPJesseRW: XLK probably takes the cleanest hit on a hold too, not just from duration. The leverage-heavy software names feel it first when refinancing stays expensive
2
Report
318
General
D1ane
·
10-20 13:04

💰 From SpaceX to Anthropic: Who Will Really Benefit From the AI Wealth Boom?

AI could create enormous wealth. But who will actually get a share of it? Elon Musk has sparked discussion after saying he would give one $SpaceX(SPCX)$  share to every child in America through Trump accounts, according to Dow Jones. The announcement raises a bigger question about the technology industry: as AI companies grow in value, how much of that wealth will reach ordinary people rather than remain concentrated among founders, employees and early investors? This is more than a story about billionaires giving away shares. It touches on private-company valuations, employee ownership, financial access and the growing debate over who benefits from technological progress. 🚀 1. SpaceX: A Share Is Not the Same as Cash Musk’s proposal has
💰 From SpaceX to Anthropic: Who Will Really Benefit From the AI Wealth Boom?
TOPcheeryk: Private valuation talk is fine, but without Starlink cash flow and launch contract detail, that stake is more symbolism than value
1
Report
444
General
D1ane
·
10-20 13:01

⚡ AI’s Next Winners May Not Be Tech Stocks: Why $MMM Deserves Attention

What if one of the opportunities created by the AI boom is hiding in an industrial company rather than a technology stock? When investors discuss AI infrastructure, names such as $m$NVIDIA(NVDA)$ , $Amazon.com(AMZN)$ and $Microsoft(MSFT)$  often dominate the conversation. But building and operating data centres requires much more than powerful chips and cloud computing. It also requires industrial materials, specialised components, reliable infrastructure and solutions that help facilities operate efficiently. That is why the latest announcement involving $3M(MMM)$ and Amazon is worth watching. Ac
⚡ AI’s Next Winners May Not Be Tech Stocks: Why $MMM Deserves Attention
TOPglimmzy: Industrial suppliers are still underpriced in this AI buildout, but the real work is figuring out how much of that Amazon tie-up actually flows into earnings
1
Report
300
Selection
Kentzw
·
10-20 15:09

🚀 SpaceX Earnings: $100 Billion Revenue Ambition, but at What Cost?

SpaceX is no longer just a rocket company. It’s becoming an AI infrastructure, satellite communications and connectivity business — and Wall Street wants to know whether the numbers will add up. SpaceX’s third-quarter earnings report is attracting attention for a reason. According to a recent Dow Jones report, the company is expected to return to profitability, with revenue forecast to reach $12.8 billion, up 64% from the same period last year. But the headline figures only tell part of the story. Behind the growth is an ambitious plan to build AI computing capacity, expand Starlink and develop next-generation rockets. These businesses could create multiple sources of future revenue, but they also require enormous amounts of capital. The big question isn’t simply how fast SpaceX is growing
🚀 SpaceX Earnings: $100 Billion Revenue Ambition, but at What Cost?
TOPLeilaLynch: 64% growth is strong, but AI capacity only works if the payback window stays tight enough. Starlink cash flow may end up funding more than the launch business here
1
Report
226
Selection
Kentzw
·
10-20 15:15

🎬 $NFLX Earnings: Netflix Is Fighting for Something Money Can’t Easily Buy — Our Attention

Netflix has become one of the biggest names in entertainment, but its next challenge may be harder than producing another hit series. Can Netflix keep people watching when viewers have more entertainment choices than ever before? Netflix is due to report its third-quarter results, and investors will be looking beyond revenue growth to assess whether the streaming giant can maintain its momentum as competition intensifies. According to Reuters, Netflix is expected to report revenue of approximately $12.87 billion, representing 11.8% year-over-year growth. That would be its slowest third-quarter revenue growth in three years. The company is still growing, but the market wants to understand what comes next. For me, the most interesting part of this story isn’t simply the revenue forecast. It’
🎬 $NFLX Earnings: Netflix Is Fighting for Something Money Can’t Easily Buy — Our Attention
TOPfrostiix: I think the slowdown is fine if ad tier penetration beats guide. APAC subs can still offset North America maturity better than people think
1
Report
50.80K
Selection
UOB Asset Management
·
10-19

Asia turns the tables on dividends

UOBAM Ping An FTSE ASEAN Dividend Index ETF: $UOBAM PA FT ASEAN DV S$(UPD.SI)$ $UOBAM PA FT ASEAN DV US$(UPU.SI)$ United Asia Fund: $UNITED ASIA "A" (SGD) INC(SGXZ90724238.SGD)$ $UNITED ASIA "A" (SGD) ACC(SG9999001051.SGD)$ United Greater China Fund: $UNITED GREATER CHINA "A" (SGD) ACC(SG9999001093.SGD)$ The global dividend landscape is evolving. Rounding out our Asia series, we look at why Asian companies, especially those in ASEAN, have emerged as a reliable source of income, with dividend payouts that increasingly surpass those
Asia turns the tables on dividends
TOPJeromeErnest: This probably does self reinforce a bit. Higher inflows can compress yields, and the bigger watch item is whether Asian firms stick with dividends or drift toward buybacks too
2
Report
1.10K
General
PeterDiCarlo
·
10-20 15:33

5 Stocks at Key Buy Zones: $COHR, $AMZN, $SMCI, $HD & $STZ

Five stocks are approaching or reacting to important technical levels. Some are showing bullish momentum already, while others may be setting up for a bounce. Here’s what I’m watching. ✅ $Coherent(COHR)$ — $220 Is the Key Level The bullish market structure remains intact as long as COHR holds above $220. If support holds, a bounce is the expected scenario. 🚀 $Amazon.com(AMZN)$ — Breaking Out AMZN is breaking out of its Daily Institutional Buy Zone, historically a strong area for the stock. Buyers appear to be stepping in, and the breakout is worth watching for follow-through. 🔍 $SUPER MICRO COMPUTER INC(SMCI)$ — Testing Monthly Support After being rejected at wed
5 Stocks at Key Buy Zones: $COHR, $AMZN, $SMCI, $HD & $STZ
Comment
Report
3.79K
Selection
Tiger_Earnings
·
10-20 15:52

[Stock Prediction] Netflix Earnings: Can Growth Outrun Slowing Engagement?

$Netflix(NFLX)$ reports Q3 earnings after the U.S. market closes on October 20.Wall Street expects revenue of about $12.87 billion, up roughly 11.8% year over year, with EPS around $0.83. Are people spending less time on Netflix? Recent data points to softer engagement in the U.S. User churn has moved higher, app downloads in the U.S. and Canada have weakened, and average monthly viewing time has fallen from where it was a few years ago. That matters because Netflix is no longer just competing with Disney or HBO. It is also fighting for attention against YouTube, TikTok and other platforms that keep users watching for hours. At the same time, Netflix is trying to build new growth engines. Its ad-supported business is expanding, but
[Stock Prediction] Netflix Earnings: Can Growth Outrun Slowing Engagement?
# Earning Season
TOP苏36: My Prediction: C — Between -5% and +5% Netflix's biggest challenge isn't profitability; it's proving its next growth engine can offset weakening user engagement. Revenue is expected to reach $12.87 billion, up 11.8% year over year. Advertising revenue, pricing power and live programming offer upside. However, US churn reportedly rose 16.6% year over year in Q3, while app downloads in the US and Canada fell 20%. Competition from YouTube and short-form videos is becoming harder to ignore. I expect earnings could meet or slightly beat expectations, but that alone may not trigger a sustained rally. Investors will focus on forward guidance, advertising monetization and whether Netflix can reignite engagement. Recent layoffs and content leadership changes add uncertainty. My verdict: C.Unless management delivers a convincing growth outlook, a sharp post-earnings breakout looks difficult to justify. Netflix needs to prove viewers are staying, not just paying. @Tiger_Earnings [安慰]
11
Report
274
General
pretiming
·
10-20 15:16

U.S. Market Outlook | October Correction Underway and Key November Turning Point

$S&P 500(.SPX)$ $SPDR S&P 500 ETF Trust(SPY)$ $NASDAQ 100(NDX)$ $Invesco QQQ(QQQ)$ $Dow Jones(.DJI)$ $Global X Dow 30 Covered Call ETF(DJIA)$ $iShares Russell 2000 ETF(IWM)$ $Cboe Volatility Index(VIX)$ As anticipated in our previous market outlook, the U.S. stock market’s weekly trend has now passed the early-October period, with a short-term peak having formed and the market entering a correction phase. Our existing outlook remains unchanged. The
U.S. Market Outlook | October Correction Underway and Key November Turning Point
Comment
Report
208
Selection
Tiger_SG
·
10-20 15:32
A share price only shows you the surface, so how do you tell a high-quality company from a lucky one? Join us on 29 October for “Fundamental Analysis 101: Beyond the Stock Price” with Jonathan Lo, Investment Representative at Tiger Brokers (Singapore), and learn how to read financial statements, use ratios like P/E, P/B and ROE, spot sustainable economic moats, and track sector rotation across the economic cycle.

[Event Registration, For Lv1 - 6 Users] 29 October|Fundamental Analysis 101: Beyond the Stock Price

@TigerEvents：
A company’s share price rarely tells the whole story. To build long-term confidence in the markets, investors need a structured framework to measure financial stability, business moats and macroeconomic sentiment. Join Jonathan Lo, Investment Representative at Tiger Brokers (Singapore), who brings nearly 20 years of practical trading and investment experience and interprets markets through multi-asset, macro-directed long-short strategies across equities and options. In this session, he will show you how to analyze financial statements, use key balance sheet and valuation ratios (P/E, P/B, ROE), identify sustainable economic moats, and track GICS sector rotation across different stages of the economic cycle. By the end of the sesison, you'll be equipped with the analytical tools to identif
[Event Registration, For Lv1 - 6 Users] 29 October|Fundamental Analysis 101: Beyond the Stock Price
A share price only shows you the surface, so how do you tell a high-quality company from a lucky one? Join us on 29 October for “Fundamental Analys...
Comment
Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

All